Toxicity and survival associated with IV/IP chemotherapy following neoadjuvant chemotherapy and interval debulking surgery for epithelial ovarian, fallopian tube, and primary peritoneal cancer

被引：0
|
作者：
Rios-Doria, E. [1 ]
Pezzillo, M. [1 ]
Ulm, M. A. [2 ]
Tillmanns, T. [2 ]
机构：
[1] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA
[2] Univ Tennessee, West Canc Ctr, Memphis, TN USA
来源：
GYNECOLOGIC ONCOLOGY | 2020年 / 159卷
关键词：
D O I：
10.1016/j.ygyno.2020.05.157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
269
引用
收藏
页码：127 / 128
页数：2
相关论文
共 50 条
  • [41] Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection
    Gill, Sarah E.
    McGree, Michaela E.
    Weaver, Amy L.
    Cliby, William A.
    Langstraat, Carrie L.
    GYNECOLOGIC ONCOLOGY, 2017, 144 (02) : 266 - 273
  • [42] Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009
    Tiersten, Amy D.
    Liu, P. Y.
    Smith, Harriet O.
    Wilczynski, Sharon R.
    Robinson, William R., III
    Markman, Maurie
    Alberts, David S.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (03) : 444 - 449
  • [43] Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer
    Iura, Ayaka
    Takita, Morihito
    Kawano, Aiko
    Imai, Kazuaki
    Konnai, Katsuyuki
    Onose, Ryo
    Kato, Hisamori
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2018, 29 (05)
  • [44] Comparative analysis of neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer
    Sirop, S. J.
    Saha, S.
    Iddings, D.
    Ghanem, M.
    Dutt, N.
    Metz, J.
    Wilson, D.
    Weise, D.
    Arora, M. L.
    Singh, T.
    Eilender, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [45] Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma
    Seward, Shelly M.
    Winer, Ira
    CANCER AND METASTASIS REVIEWS, 2015, 34 (01) : 5 - 10
  • [46] Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma
    Shelly M. Seward
    Ira Winer
    Cancer and Metastasis Reviews, 2015, 34 : 5 - 10
  • [47] Neoadjuvant Chemotherapy or Primary Debulking Surgery for Stage IIIC Ovarian Cancer
    Copur, Mehmet Sitki
    Gauchan, Dron
    Ramaekers, Ryan
    Crockett, David
    Clark, Douglas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) : 802 - 802
  • [48] Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer
    Vergote, IB
    De Wever, I
    Decloedt, J
    Tjalma, W
    Van Gramberen, M
    van Dam, P
    SEMINARS IN ONCOLOGY, 2000, 27 (03) : 31 - 36
  • [49] Factors that predict optimal debulking at interval cytoreductive surgery after neoadjuvant chemotherapy in epithelial ovarian cancer
    Boccaccio, R. B.
    Crim, A. K.
    Osborn, K.
    Ding, K.
    Moore, K. N.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 82 - 82
  • [50] The management of epithelial ovarian cancer: neoadjuvant chemotherapy and interval surgery
    Allen, D. G.
    SOUTHERN AFRICAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2010, 2 (02) : 67 - 68
12345